I agree the Ann is confusing the market while it could be clearer with details and directions. But it shouldn’t be read as holding off revenue or other chances. Just read what TK says in the Ann again I think he has been quite specific.
”We are pleased to be working with the global consumer healthcare team on a unique and important standalone product that neatly complements the solutions in our existing portfolio”
The portfolio in below chart should be what TK refers to - telehealth, clinical use, 3rd world and direct to Consumer. This Sanofi option was not prioritized 2 months ago but now came out before others thanks to Sanofi’s invitation. I am pretty sure RAP sales team are still working with LM, Ping an good doctor, German hospital etc for a deal, which are based on our CE & TGA approved products, prior to the outcome of collaboration with Sanofi.
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp Grants Option to Consumer Health Division of Sanofi
Ann: ResApp Grants Option to Consumer Health Division of Sanofi, page-137
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 128 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online